The only long acting somatostatin analog that is ready-to-use in a prefilled syringe

Somatuline^® Depot (lanreotide) Injection

Now there's a simple, effective way to treat your patients with acromegaly: Somatuline Depot, the only somatostatin analog available in a prefilled syringe.

Somatuline^® Depot (lanreotide) Injection is injected deep subcutaneously in a two-step procedure that's simple for you and for your patients.1 With a short, 20 mm needle, and an injection volume of just 0.3 mL to 0.5 mL, injections are designed to be patient- and professional-friendly.1

To make Somatuline^® Depot (lanreotide) Injection accessible to as many patients as possible, it is expected to be covered by the majority of payers and widely available, including leading specialty pharmacies.2

Learn more about Somatuline^® Depot (lanreotide) Injection.

About acromegaly

Read about acromegaly, how it affects the body, and how it can be treated.

How Somatuline^® Depot (lanreotide) Injection is injected

Only Somatuline^® Depot (lanreotide) Injection comes in a ready-to-use, prefilled syringe and has a simple, two-step injection procedure.1

Who should take Somatuline^® Depot (lanreotide) Injection

See if Somatuline Depot is the right treatment option for your patients with acromegaly.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot (lanreotide) Injection 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot (lanreotide) Injection may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

SOMATULINE^® DEPOT (LANREOTIDE) INJECTION IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

Somatuline® Depot (lanreotide) Injection

About acromegaly

How Somatuline® Depot (lanreotide) Injection is injected

Who should take Somatuline® Depot (lanreotide) Injection

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection

How Somatuline^® Depot (lanreotide) Injection is injected

Who should take Somatuline^® Depot (lanreotide) Injection